Twitter LinkedIn
    Wednesday, October 4
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Deals & Transactions»Hedge fund Marshall Wace seeks venture capital deals
    Deals & Transactions

    Hedge fund Marshall Wace seeks venture capital deals

    February 9, 20212 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    London-based Marshall Wace, which manages about $52bn in assets, is raising as much as $400m for a fund that will invest in privately owned healthcare companies, according to people familiar with its plans. The strategy is to buy them before flotation and then hold on to them after they list.

    The Marshall Wace and Third Point launches underscore how the lines between the hedge fund and private equity industries are becoming increasingly blurred, as managers trading highly priced public markets look for new sources of returns. The new fund, which will lock up investors’ cash for a number of years, will aim to invest in companies that are between about six and 24 months away from going public, in areas such as biotechnology, medical technology and life sciences. It is likely to invest in companies in the US, Europe and Asia.

    The healthcare sector has been in investors’ focus over the past year as drugs companies have raced to develop treatments and vaccines to combat the Covid-19 pandemic. Marshall Wace already holds about $10bn of investments in listed healthcare assets, including the effects of leverage.

    Its flagship Eureka fund and its Tops (Market Neutral) fund, which analyses buy and sell recommendations from about 1,000 external analysts at banks and research houses to determine its bets, both gained more than 14 per cent last year, according to investors. In January Eureka lost 1.5 per cent, and Tops (Market Neutral) gained 3.8 per cent.

     

    Read more at Financial Times

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    2021 deals and transactions Investments Private Equity
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Animal drugs maker Dechra agrees to lower £4.5bn takeover by Swedish private equity firm EQT

    June 3, 2023

    Warburg and Advent in the lead to acquire Baxter’s biopharma unit

    May 13, 2023

    BlackRock Sells Asset-Backed Bonds From Credit Suisse’s Books

    April 14, 2023

    KKR buys stake in communications firm FGS Global

    April 11, 2023

    Comments are closed.

    Other Articles

    CVC agrees to acquire a $470m stake in Aleph Holding, valuing the company at $2bn

    July 12, 2021

    Gaw Capital Said to Weigh $200 Million SPAC for Asia Tech Deals

    February 26, 2021

    Kier completes £110m sale of housing arm to private equity buyer

    May 28, 2021

    RiverGlade Capital closes $453m Healthcare Fund II

    August 22, 2022

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?